Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, ...
June 12, 2006 (Atlanta) — Women with breast cancer who are treated with the aromatase inhibitor anastrozole (Arimidex, AstraZeneca) for 5 years can lose 6% to 7% in bone-mineral density (BMD), enough ...
Erratum: Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial The ...
Anastrozole, an aromatase inhibitor, is widely prescribed for oestrogen receptor-positive breast cancer. Although effective, it has been linked to autoimmune hepatitis (AIH), a rare but serious ...
A recent study published in Scientific Reports investigated iron-doped boron nitride nanoparticles (Fe-BNNPs) as potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback